How Far Apart Should Low-Dose Ketamine Treatments Be Spaced?

Low-dose ketamine treatments are typically spaced two to three times per week during an initial induction phase lasting two to three weeks, then stretched to every two to six weeks for maintenance dosing, depending on how long symptom relief lasts for a given patient. There is no single fixed interval that applies to everyone: spacing is individualized based on symptom recurrence, side effects, and the treatment route (intravenous, intramuscular, oral, or intranasal esketamine). Low-dose ketamine for depression and chronic pain is prescribed off-label except for esketamine (Spravato), which the FDA approved in 2019 for treatment-resistant depression alongside an oral antidepressant.

This article explains what the published evidence shows about spacing during both phases, the factors that push an interval shorter or longer, and why treatment frequency should be set and adjusted by the prescribing clinician rather than by the patient. This is educational content, not medical advice, talk with your prescriber about the schedule that fits your response and health history.

Induction phase: why sessions start close together

The induction phase is the first block of treatments used to establish whether a patient responds to ketamine at all. Early trials of intravenous ketamine for depression, including work supported by the National Institute of Mental Health (NIMH), an agency within the U.S. Department of Health and Human Services that funds mental health research, found that a single infusion often produced only a transient antidepressant effect lasting days. Repeated dosing close together, commonly two to three sessions per week for two to three weeks, was studied as a way to extend and consolidate that initial response before spacing out further.

This is the same rationale behind the FDA label for esketamine, which specifies twice-weekly nasal spray sessions for the first four weeks. That labeled schedule is the most rigorously tested spacing protocol available, since it comes from randomized controlled trials submitted for drug approval rather than open-label case series, which make up much of the evidence for other low-dose ketamine formulations and routes. If you're weighing dose and route together, see this ketamine dosing and administration overview and the related discussion of low dose ketamine dosing by body weight.

Maintenance phase: spacing is individualized, not fixed

Once a patient responds during induction, most protocols shift to a maintenance phase with sessions spaced further apart, often every two, three, or four weeks, and sometimes longer. Unlike induction, there is no single trial-validated interval for maintenance dosing. Clinicians typically titrate spacing by tracking how long a given patient's improvement holds before symptoms begin returning, then scheduling the next session shortly before that expected relapse window. This makes symptom tracking between sessions a practical part of the protocol, not an afterthought, see ketamine tolerance for how repeated dosing intervals interact with response durability over time.

The FDA label for esketamine reflects this same individualization principle after induction: it moves to weekly dosing for weeks five through eight, then to dosing every one or two weeks based on the physician's assessment of continued need. That built-in flexibility, formalized in an approved drug label, is a reasonable model for how off-label low-dose ketamine spacing decisions are typically approached in practice, even though the evidence supporting specific off-label intervals is thinner. For a broader view of how long any single session's effects tend to last, see how long ketamine effects last.

What actually changes the ideal interval

Several factors shift spacing away from a generic schedule, and a prescriber typically weighs them together rather than applying a fixed calendar:

• Route of administration: intravenous and intramuscular dosing act faster and clear faster than oral or sublingual ketamine, which can change how long a single dose's effect persists and how soon the next one is needed.
• Indication: depression and chronic pain protocols have been studied with different dosing cadences, and relief durability appears to vary by condition, see sub-anesthetic dose ranges for how dose and indication interact.
• Side effect burden: dissociative or blood pressure effects that build up with frequent dosing may push a clinician toward wider spacing even if symptom relief would support closer sessions.
• Age and comorbidities: older adults and patients with cardiovascular conditions are often monitored more conservatively; see ketamine therapy in older adults for related safety considerations.
• Combination treatment: patients using ketamine alongside other interventions may follow a different cadence than monotherapy protocols, discussed in combination therapy protocols.

The evidence gap you should know about

Most published data on ketamine spacing comes from small, open-label studies or case series rather than large randomized trials designed specifically to test different maintenance intervals against each other. Esketamine's labeled schedule is the exception, backed by controlled trial data submitted to the FDA. For off-label intravenous, intramuscular, or oral low-dose ketamine, spacing recommendations are largely extrapolated from induction-phase trial data and clinical experience rather than head-to-head interval comparisons. That means a "standard" maintenance interval you might read online is a common practice pattern, not a proven optimum. If you're new to how these protocols are typically structuredgetting started with low-dose ketamine covers how induction and maintenance phases fit together, and ketamine depression dose covers dose ranges used alongside spacing decisions.